Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | ILK | Q13418 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4284782 | 0.98 | MAPT (0.43) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL13654389 | 0.83 | BACE1 (0.53) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL17080670 | 0.78 | CYP2A6 (0.58) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL7898110 | 0.77 | CA2 (0.55) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL18878582 | 0.77 | CYP2A6 (0.41) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL6121215 | 0.76 | CYP2A6 (0.39) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL1530760 | 0.75 | CYP2A6 (0.37) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL14756124 | 0.75 | CYP2A6 (0.42) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL5646366 | 0.74 | CYP2A6 (0.38) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL16693109 | 0.74 | CYP2A6 (0.38) | MAPTALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022263557-A1 | PHARMACEUTICAL COMPOUND | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-12-22 | — | — | WO | disclosed |
| US-10414762-B2 | Amides of acetic and propionic acids | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-09-17 | — | — | US | disclosed |
| US-10414762-B2 | Amides of acetic and propionic acids | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-09-17 | — | — | US | disclosed |
| US-20190010150-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-01-10 | — | — | US | disclosed |
| US-9914729-B2 | Amides of acetic and propionic acids | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-03-13 | — | — | US | disclosed |
| US-9914729-B2 | Amides of acetic and propionic acids | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-03-13 | — | — | US | disclosed |
| US-9914729-B2 | Amides of acetic and propionic acids | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-03-13 | — | — | US | disclosed |
| US-20170183339-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | BAYER HEALTHCARE AG (DE) | 2017-06-29 | — | — | US | disclosed |
| US-20170183339-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | BAYER HEALTHCARE AG (DE) | 2017-06-29 | — | — | US | disclosed |
| US-20170183339-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | BAYER HEALTHCARE AG (DE) | 2017-06-29 | — | — | US | disclosed |
| US-20090258898-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258898-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258898-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| US-7553851-B2 | Amides of acetic and propionic acids | BAYER HEALTHCARE AG (DE) | 2009-06-30 | — | — | US | disclosed |
| US-7553851-B2 | Amides of acetic and propionic acids | BAYER HEALTHCARE AG (DE) | 2009-06-30 | — | — | US | disclosed |
| US-7553851-B2 | Amides of acetic and propionic acids | BAYER HEALTHCARE AG (DE) | 2009-06-30 | — | — | US | disclosed |
| US-20070037844-A1 | 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-bromo-1-benzothien-2-yl)acetamide hydrochloride; nicotinic receptor agonists; cognition activators; learning enhancement; nootropic agents; demetia; cholinergic agents; Alzheimer's disease; brain traumas; stroke; attention deficit disorder; schizophrenia | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037844-A1 | 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-bromo-1-benzothien-2-yl)acetamide hydrochloride; nicotinic receptor agonists; cognition activators; learning enhancement; nootropic agents; demetia; cholinergic agents; Alzheimer's disease; brain traumas; stroke; attention deficit disorder; schizophrenia | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037844-A1 | 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-bromo-1-benzothien-2-yl)acetamide hydrochloride; nicotinic receptor agonists; cognition activators; learning enhancement; nootropic agents; demetia; cholinergic agents; Alzheimer's disease; brain traumas; stroke; attention deficit disorder; schizophrenia | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| EP-1487835-B1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | BAYER HEALTHCARE AG (DE) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183339-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | HCAR2, HCAR3, NAAA | MAPT 587/4885ALDH1A1 366/4885KDM4E 3215/4885 |
| US-20190010150-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | HCAR2, HCAR3, NAAA | MAPT 587/4885ALDH1A1 366/4885KDM4E 3215/4885 |
| US-20090258898-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | HCAR2, HCAR3, NAAA | MAPT 587/4885ALDH1A1 366/4885KDM4E 3215/4885 |
| US-20070037844-A1 | 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-bromo-1-benzothien-2-yl)acetamide hydrochloride; nicotinic receptor agonists; cognition activators; learning enhancement; nootropic agents; demetia; cholinergic agents; Alzheimer's disease; brain traumas; stroke; attention deficit disorder; schizophrenia | CHRNA2, CHRNA6, CHRNA5 | MAPT 136/4885ALDH1A1 294/4885KDM4E 2530/4885 |
| US-10414762-B2 | Amides of acetic and propionic acids | HCAR2, HCAR3, NAAA | MAPT 587/4885ALDH1A1 366/4885KDM4E 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.